Daiichi Sankyo (4568.T) and Merck's (MRK) Biologics License Application for ifinatamab deruxtecan has been accepted and granted Priority Review by the FDA for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. The PDUFA date, the FDA action date for its regulatory decision, is October 10, 2026.
Ifinatamab deruxtecan is a specifically engineered, B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and Merck.
Daiichi Sankyo shares are trading at 2,732 yen, down 1.48%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.